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ABSTRACT
We address the problem of high-dose-rate brachytherapy treatment
planning for prostate cancer. e problem involves determining a
treatment plan consisting of the so-called dwell times that a radi-
ation source resides at different positions inside the patient such
that the prostate volume and the seminal vesicles are covered by
the prescribed radiation dose level asmuch as possiblewhile the or-
gans at risk, e.g., bladder, rectum, and urethra, are irradiated as lit-
tle as possible. e problem is highly constrained, following clini-
cal requirements for radiation dose distributionwhile the planning
process for treatment planners to design a clinically-acceptable
treatment plan is strictly time-limited. In this paper, we propose
that the problem can be formulated as a bi-objective optimization
problem that intuitively describes trade-offs between target vol-
umes to be radiated and organs to be spared. We solve this problem
with the recently-introduced Multi-Objective Real-Valued Gene-
pool Optimal Mixing Evolutionary Algorithm (MO-RV-GOMEA),
which is a promising MOEA that is able to effectively exploit de-
pendencies between problem variables to tackle complicated prob-
lems in the continuous domain. MO-RV-GOMEA also has the capa-
bility to perform partial evaluations if problem structures allow lo-
cal variations in existing solutions to be efficiently computed, sub-
stantially accelerating the overall optimization performance. Ex-
periments on real medical data and comparison with state-of-the-
art MOEAs confirm our claims.
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1 INTRODUCTION
Radiotherapy is a frequently used form of treatment for cancer.
Brachytherapy (BT) [14] is a form of internal radiotherapy where
radiation sources are placed inside, or passed through, the patient’s
body, close to the tumors, as opposed to the External Beam Radi-
ation erapy (EBRT) where radiation is directed at the tumors
from outside the patient’s body. A potential advantage of BT is
that due to its local nature, the radioactive dose distribution can
be shaped to conform to the shape of the treatment volume beer,
and healthy surrounding organs/tissues can thus be spared from
undesired radiation risks. Furthermore, the most common way to
apply BT, the so-called High-Dose-Rate (HDR) BT, is by using a ra-
dioactive source with a high strength, resulting in fewer radiation
treatment fractions. In this paper, we focus on HDR-BT treatment
for prostate cancer but the methodology can be straightforwardly
adapted to other types of BT involving radioactive sources with
1372
GECCO ’17 Companion, July 15-19, 2017, Berlin, Germany Luong et. al.
a lower strength. To deliver radiation sources to the target vol-
umes (i.e., the prostate, and in some cases, the seminal vesicles),
normally, 14-20 catheters (depending on the prostate size) are in-
serted into patient’s body through the transperineal skin. ese
catheters are connected to a device, called the aerloader, which
controls the movement of radiation sources through the catheters.
Each catheter has a certain number of dwell positions where the
source can pause to release radiation for a certain amount of time,
termed dwell time, before moving to the next position. e longer
the dwell time at a dwell position, the more radioactive dose is dis-
tributed to the surrounding volume. e list of all dwell times at
all dwell positions comprises an HDR-BT treatment plan. Mak-
ing a clinically-acceptable BT plan is not a trivial task, and in-
volves many clinical requirements that need to be satisfied. On the
one hand, dwell times should be long enough to cover the target
volumes as much as possible with a certain prescribed radiation
dose, effectively sterilizing cancer cells. On the other hand, dwell
times should be as short as possible to keep the radiation deliv-
ered to normal tissues and other nearby Organs At Risk (OARs),
i.e., urethra, rectum, bladder, under certain clinically-acceptable
upper bounds. Aiming to cover the target volumes while sparing
OARs, BT treatment planning is intrinsically amulti-objective opti-
mization problem, where a single utopian solution (i.e., a treatment
plan) that optimizes all objectives at the same time does not exist.
Instead, there exists the Pareto-optimal set of non-dominated solu-
tions, that are optimal in the sense that improving any objective of
these solutions deteriorates their other objectives. e image set
of the Pareto-optimal set in the objective space forms the so-called
Pareto-optimal front that exhibits the possible trade-offs between
the involved objectives. e goal then in multi-objective optimiza-
tion is to find a so-called approximation set of solutions that is as
close as possible to the optimal Pareto set of solutions, oen mea-
sured in the objective space.
Available BT treatment planning soware packages, see e.g., [5,
7, 10], however, do not tackle the problem in a truemulti-objective
manner. Instead, all the objectives following from the clinical re-
quirements are combined into a single optimization function by
the weighted-sum approach, obtaining thus a single solution that
corresponds with each seing of the weighting coefficient vector.
e proper seing of these weights can hardly be determined a pri-
ori because it involves taking into account the geometry of the pa-
tient’s organs, the configuration of the inserted catheters, and the
preferences of the treating physician. Weighted-sum approaches
with some rule-of-thumb coefficient seings oen return treatment
plans that do not match the trade-off that individual radiation on-
cologists prefer for specific patients. erefore, BT treatment plan-
ners (i.e., radiation oncologists, radiation therapy technologists,
and clinical physicists) oen need to spend time to manually ad-
just the treatment plan until satisfied, sometimes up to an hour.
In this paper, we tackle BT treatment planning in the true multi-
objective optimization manner, approximating the set of optimal
trade-offs between target volumes coverage versus OARs sparing.
Such an approximation set explicitly quantifies and exhibits the
compromises that need to be made. Treatment planners can make
use of the obtained approximation set as a decision support tool to
quickly locate the desired trade-off solution, which can be further
adjusted, to arrive at a final plan.
e HDR-BT treatment procedure is time-constrained, where
the planning task should normally be finalized within one hour.
Optimization algorithms need to spend a certain number of itera-
tions including treatment plan evaluations before acceptable plans
can be obtained. BT treatment plan evaluation is a time-consuming
operation, which involves calculations of the radiation dose dis-
tribution at target volumes and OARs. In this paper, we present
how the dependency structure of dwell positions can be used to en-
hance the efficiency in generating promising candidate treatment
plans. Such dependency knowledge can be acquired online by per-
forming linkage learning during the optimization process or can
be computed offline based on the geometry information of the im-
planted catheters. Always performing a full evaluation of treat-
ment plans is unnecessary, especially if the offspring solutions dif-
fer from parent solutions at only a few dwell times. erefore, the
solving time can be substantially improved if local changes of treat-
ment plans can be computed. To this end, we use the recently-
introduced Multi-Objective Real-Valued Gene-pool Optimal Mix-
ing EvolutionaryAlgorithm (MO-RV-GOMEA) [2], which has been
shown to have superior performance on benchmark problems due
to its capabilities of exploiting linkage information and perform-
ing partial evaluations in the context of continuous optimization.
Here, we aim to see the impact of the advantages that MO-RV-
GOMEA has to offer in solving the BT treatment planning problem
compared to the well-known Multi-Objective Evolutionary Algo-
rithm (MOEA) NSGA-II [4] and the Multi-Objective Estimation-of-
Distribution Algorithm (MOEDA) MAMaLGaM [1].
2 PROBLEM MODELING
2.1 Clinical Practice
An HDR-BT treatment for prostate cancer starts with the insertion
of a number of catheters through the area between the patient’s
scrotum and anus (i.e., the perineum) aimed at target volumes (i.e.,
the prostate and seminal vesicles). e implanted catheters (i.e.,
implant) are firmly fixed to avoid displacements. Medical images
(e.g., Computed Tomography (CT) or Magnetic Resonance Imag-
ing (MRI) scans) of the patient’s pelvic area are then acquired to
be employed in the following treatment planning session. Treat-
ment planners first draw the contours of the treatment targets and
OARs on the obtained CT/MRI scans in BT treatment planning so-
ware. e inserted catheters are also delineated. Each catheter
is discretized into a number of dwell positions where radiation
sources can dwell, normally by a step size of 2.5 mm beginning
from the first dwell position which is offset 5.0 mm from the tip
of the catheter. To ensure the treatment targets are sufficiently
treated while sparing OARs from radiation risks, only dwell posi-
tions within the target volumes expanded with a margin of 5.0mm
are activated. Dwell positions outside these volumes are kept inac-
tive, which means they will not be considered when the treatment
plan is made. e longer the time a source dwells at an active posi-
tion (i.e., dwell time), the more radiation is delivered to surround-
ing tissues. A certain dose level is prescribed by radiation oncol-
ogists which is deemed sufficient to sterilize tumor cells for the
specific tumor type. Dwell times should then be configured such
that the entire prostate should receive at least the prescribed dose,
1373
Efficient, Effective, and Insightful Tackling of the High-Dose-Rate Brachytherapy Treatment Planning Problem for Prostate Cancer using
Evolutionary Multi-Objective Optimization Algorithms GECCO ’17 Companion, July 15-19, 2017, Berlin, Germany
but not toomuch in order to allow healthy cells, which are less sus-
ceptible to radiation than tumor cells, to recover from being radi-
ated. On the one hand, treatment plans with very long dwell times
can kill all tumor tissues but can also cause undesirable damage to
healthy tissues (i.e., necrosis, which is considered life-threatening).
On the other hand, treatment plans with too short dwell times can
spare healthy tissues, but insufficiently-treated tumor cells can still
grow, making the whole treatment ineffective. BT treatment plan-
ners need to make a proper treatment plan that satisfies general
clinical requirements as well as special criteria for each specific
case. e approved plan is then used to treat the patient. e aer-
loader, which is connected to the inserted catheters, controls the
movements of the radiation source through the catheters such that
the source stays at each dwell position for the amount of time as
indicated in the approved plan.
2.2 Dose Distribution Evaluation
Each treatment plan (i.e., a specific configuration of dwell times)
brings about a dose distribution in the surrounding tissues. A plan
is deemed clinically acceptable if its dose distribution satisfies the
clinical requirements. A utopian plan that radiates all tumor cells
with the prescribed dose while delivering no radiation to OARs
never exists. Clinical requirements therefore oen indicate the
sufficient lower bounds of radiating target volumes and allowable
upper bounds of radiating OARs. A widely-used set of clinical
requirements, termed Dose-Volume (DV) V ox criteria (or require-
ments), specify how large the cumulative volume of an organ o re-
ceiving at least the radiation dose level x should be. For example,
it is oen recommended that V
prostate
100 ≥ 95%, i.e., at least 95% of
the prostate volume should be covered by 100% of the prescribed
dose [6]. To treat tumor cells possibly existing in the vesicles, the
requirement V vesicles80 ≥ 95% can be employed to indicate that at
least 95% of the volume of the vesicles should receive 80% of the
prescribed dose. To prevent hot spots forming inside the prostate
(i.e., the part of prostate that is radiated too much), it is required
that V
prostate
200 ≤ 20%, i.e., not more than 20% of the prostate volume
should be covered by 200% of the prescribed dose. Similarly, to pro-
tect OARs from radiation risks, there are DV criteria for each organ
that set the upper bounds of the radiation levels that can be allowed
to be delivered to that organ. For example,V rectum78 ≤ 1 cm
3, i.e., the
rectum volume covered by 78% of the prescribed dose should not
exceed 1 cubic centimeter (cm3), or V bladder74 ≤ 2 cm
3, i.e., the blad-
der volume receiving at least 74% of the prescribed dose should
not be more than 2 cm3. Table 1 presents the DV indices and
their corresponding requirements currently employed at the Aca-
demic Medical Center (AMC), the hospital involved in this study.
tf It is impossible to calculate the radiation received by every sin-
Prostate Bladder Rectum Urethra Vesicles
V100 ≥ 95% V86 ≤ 1 cm
3 V78 ≤ 1 cm
3 V110 ≤ 0.1 cm
3 V80 ≥ 95%
V150 ≤ 50% V74 ≤ 2 cm
3 V74 ≤ 2 cm
3
V200 ≤ 20%
Table 1: BT treatment planning DV criteria at AMC.
gle cell because the number of cells in an organ is prohibitively
large. erefore, DV index values are oen approximated by eval-
uating the radiation at a certain number of so-called dose calcula-
tion points. e strength of the employed radiation source and the
relative position between a dwell position and a dose calculation
point determine the dose rate that indicates the amount of dose ir-
radiated from the source when it resides at that dwell position to
the dose calculation point per second (i.e., Gy/s). Dose rates can be
computed based on the TG-43 protocol (the American Association
of Physicists in Medicine AAPM Task Group No. 43 Report) [12].
e total radiation at each dose calculation point is the combined
dose delivered from all the active dwell positions corresponding to
the dwell times of the treatment plan. Let D be the set of all dose
calculation points, |D | = nD . LetT be the set of all dwell positions,
|T | = nT . With a certain source strength, R is an nD × nT matrix
where Ri j indicates the dose rate associated with dwell position j
and dose calculation point i . Let t be the vector of dwell times at
all active dwell positions (i.e., t is a treatment plan). e vector d
of the amounts of radiation received at all dose calculation points
can be computed as:
d = Rt (1)
e vector d can be seen as representing the dose distribution as-
sociated with the treatment plan t , from which the DV indices (in
Table 1) can be approximated. e dose calculation points can be
uniformly randomly generated inside each organ. Let Do be the
set of all dose calculation points inside organ o, Do ⊂ D. e DV
index V ox in relative terms (%) can then be computed as:
V ox =
1
|Do |
∑
i ∈Do
χ (di ,x ) (2)
where di is the total amount of radiation received at the dose cal-
culation point i , and χ (di ,x ) is an indicator function:
χ (di ,x ) =
{
1 di ≥ x
0 di < x
(3)
e DV indexV ox in absolute terms (cm
3) can be straightforwardly
computed by multiplying the result from Equation 2 with the to-
tal volume of the organ o. e more dose calculation points are
used, themore accurate the approximation of the trueDV indices is
(disregarding uncertainties of delineation). However, using a large
number of dose calculation points incurs a substantial amount of
computing time, which slows down the planning process.
2.3 Optimization Constraints
BT treatment planners normally start the planning process from an
initial plan, which is generated by BT treatment planning soware
[7, 10]. Because of the difficulty in directly optimizing DV indices
due to their discrete nature (Equation 2), planning soware oen
solves simpler optimization models of the problem. erefore, DV
requirements (in Table 1) are not always satisfied by the proposed
plans. Planners need to identify the causes of the violated require-
ments and then manually adjust the plan in a local manner (i.e.,
changing the values of some dwell times). For example, dwell times
at dwell positions inside the under-radiated part of the prostate
volume can be increased if V
prostate
100 < 95%. If the plan causes many
hot spots, then very long dwell times can be decreased to reduce
V
prostate
200 . Planners oen improve DV indices one by one, giving pri-
ority to the most violated criteria. Making a DV index satisfy its re-
quirement, however, can deteriorate other indices and might make
them violate their requirements. For example, increasing V
prostate
100
1374
GECCO ’17 Companion, July 15-19, 2017, Berlin, Germany Luong et. al.
can create new hot spots (i.e., large values of V
prostate
200 ) and cause
other DV indices for OARs to exceed their recommended thresh-
olds. How good the best possible treatment plan is depends on the
quality of the implant (i.e., howwell the catheters are inserted) and
also on the geometry of the surrounding organs. When OARs are
too close to target volumes, it is difficult to achieve good DV in-
dex values for both target coverage and OARs sparing at the same
time. If the catheters are not inserted deep enough, it might be im-
possible to obtain V
prostate
100 ≥ 95% without violating V
prostate
200 ≤ 20%.
In these situations, BT treatment planners need to compromise. To
allow treatment plans that violate some part of the clinical require-
ments to some degree to be obtained in the optimization process,
we relax the thresholds of the DV requirements to enlarge the fea-
sible search space. Specifically, the upper bounds of organ sparing
indices are increased four times. For example, V bladder74 ≤ 2 cm
3 in
the original clinical requirement becomes V bladder74 ≤ 8 cm
3. e
lower bounds of target coverage indices are also decreased in a
similar manner, e.g., V
prostate
100 ≥ 95% becomes V
prostate
100 ≥ 80%. ese
relaxed requirements, presented in Table 2, are the constraints in
our optimization model.
Prostate Bladder Rectum Urethra Vesicles
V100 ≥ 80% V86 ≤ 4 cm
3 V78 ≤ 4 cm
3 V110 ≤ 0.4 cm
3 V80 ≥ 80%
V150 free V74 ≤ 8 cm
3 V74 ≤ 8 cm
3
V200 ≤ 80%
Table 2: DV criteria from Table 1 with relaxed feasibility
thresholds. Because of the relaxation factor, V
prostate
150 has be-
come unconstrained.
2.4 Multi-Objective Optimization
BT treatment planning is a multi-objective optimization problem,
where each DV index criterion can be considered to be an optimiza-
tion objective. Optimizing target coverage indices (i.e., V
prostate
100 ,
V vesicles80 ) equals making them as large as possible (above the lower
bound thresholds) while optimizing organ sparing indices (the re-
maining indices in Table 1) equalsmaking them as small as possible
(under the upper bound thresholds). ese two groups of DV in-
dices are conflicting with each other. Each treatment plan can be
seen as a trade-off between all the involved indices. Of key inter-
est is to find the set of optimal trade-offs, termed non-dominated
solutions, where improving any DV index in one group worsens
DV indices in the other group. It is beneficial for the planners to be
informed about these best possible alternatives before approving
a plan to be used for treating the patient.
However, optimizing all DV indices of Table 2 as separate objec-
tives would result in an 8-objective optimization problem, which
is difficult to be efficiently solved. Moreover, its resulting set of
8-dimensional trade-offs is also complicated to be visualized and
interpreted. On the other hand, simply summing all indices of
a group into an objective is also not favorable since this also re-
duces the insight into key information about DV indices, namely
the minimally achieved levels. We therefore propose a bi-objective
optimizationmodel that retains important insights in trade-offs be-
tween DV indices. e two objectives are: the Least Coverage In-
dex (LCI), which corresponds to the worst-scored DV index in the
target coverage group, and the Least Safe Index (LSI), which corre-
sponds to the worst-scored DV index in the organ sparing group.
For a candidate treatment plan t , its LCI value can be considered
as:
LCI (t ) = min{V
prostate
100 ,V
vesicles
80 } (4)
e value of LCI, that we would like to maximize, is ∈ [0, 1]. e
value 0 indicates that one target volume (i.e., prostate or semi-
nal vesicles) has no dose calculation point covered by the recom-
mended dose level for that target volume. e ideal value 1 indi-
cates that the whole volume of each treatment target is covered
by the recommended dose level. e value 0.95 indicates that both
clinical requirements V
prostate
100 ≥ 95% and V
vesicles
80 ≥ 95% in Table 1
are satisfied.
Let V
o,max
x be the upper bound threshold for the dose level x
to the organ o in Table 2. e further the value of DV index V ox is
below this threshold, the beer the organ o is spared from radiation
risk. e distance of an organ sparing index V ox value below the
thresholdV o,maxx can be measured and normalized as:
δ (V ox ) = 1 −
V ox
V
o,max
x
(5)
e LSI of a candidate treatment plan t can then be defined as:
LSI (t ) = min{δ (V
prostate
150 ), δ (V
prostate
200 ), δ (V
bladder
86 ), δ (V
bladder
74 ),
δ (V rectum78 ), δ (V
rectum
74 ), δ (V
urethra
110 )}
(6)
e value of LSI, that we would like to maximize, is ∈ [0, 1]. e
value 0 indicates that one organ sparing indexV ox is currently at its
(relaxed) threshold V o,maxx . e ideal value 1 indicates that there
is no dose calculation point in any organ receiving more radiation
than its relaxed threshold dose level. Since the upper bounds of
all organ sparing indices are increased (i.e., relaxed) by a factor of
4, the value LSI = 0.75 ensures that all clinical requirements for
organ sparing indices in Table 1 are met.
e objective values of any candidate treatment plan can thus
be evaluated on these two objectives (LCI, LSI), where it can be
inferred that the values of all the other DV indices in a group are
at least as good as the representative index of that group. A treat-
ment plan satisfies all original clinical requirements in Table 1 if
its LCI ≥ 0.95 and LSI ≥ 0.75. We further argue that this model
bears resemblance with the treatment planning process in practice
in the sense that planners oen try to iteratively improve the most
violated DV index.
3 MO-RV-GOMEA
MO-RV-GOMEA [2] maintains a population of potential solutions
on which selection and variation are performed. Encountered non-
dominated solutions are stored in an adaptive elitist archive [11].
A key strength of MO-RV-GOMEA is the main variation operator
that was first introduced for the discrete GOMEA [13], and was
later adapted to the domain of real-valued variables [2]. is varia-
tion operator was shown to be able to successfully exploit linkage
structure in a wide range of optimization problems [2, 13].
Each generation of MO-RV-GOMEA starts with the selection
phase, where the selection is based on the ranking of solutions aer
non-domination sorting [4]. e selection is then partitioned into a
set of clusters, which will allow different directions of optimization
in different parts of the Pareto front. For each objective of interest,
this set of clusters contains one so-called single-objective cluster
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for which the selection procedure only considers the respective
objective. Apart from the selection, each solution in the population
is also assigned to a nearby cluster, because the Gaussian model of
one specific cluster is used in the variation of the solution.
A linkage model is used to explicitly define dependencies be-
tween subsets of variables. Each linkage model consists of a num-
ber of linkage sets, where each linkage set describes a subset of
variables that are considered to be dependent. e linkage tree
is a specific hierarchical linkage model that models a range of de-
pendencies ranging from low-level to high-level dependencies. A
linkage tree can be learned during optimization, in which case it
is learned anew at the start of each generation. e linkage tree is
initialized as a set of ℓ leaves of univariate problem indices. New
nodes are added to the tree by iteratively merging the two non-
merged nodes that are considered the most dependent by a sim-
ilarity metric, for which we use the mutual information metric,
which is derived from the sample Pearson correlation coefficient
[8]. Alternatively, a similarity metric can be defined based on the
structure of the optimization problem, leading to a linkage tree that
is fixed throughout all generations. Merging nodes continues until
the root of the tree has been created, which naturally contains the
indices of all problem variables. Each node of the linkage tree then
defines one linkage set of the linkage model.
e parameters for variation are estimated as follows. For each
linkage set of each cluster, a multivariate Gaussian probability dis-
tribution is estimated with maximum likelihood based on the se-
lection. e probability distribution of a certain linkage set covers
only the variables that are included in this linkage set. A distri-
bution multiplier is also maintained for each linkage set, which
allows the dynamic adaptation of the size of each Gaussian kernel
based on the observed direction of improvement. Per linkage set
of each cluster, the variation operation is applied to each solution
in this cluster by sampling new values from the Gaussian distribu-
tion for the problem variables described by the respective linkage
set, and inserting these into the solution. A fraction of the solu-
tions in each cluster is shied by the application of the Anticipated
Mean Shi (AMS), which shis parameters by a factor relative to
the generational difference of means. e modification of the solu-
tion is then evaluated, but only maintained if this modification is
considered to be an improvement. Otherwise, the modification is
not accepted and the solution is returned to its previous state.
We refer the interested reader to [2] for a full description of MO-
RV-GOMEA.
4 PERFORMANCE ENHANCEMENT
4.1 Exploiting Geometry Information
MO-RV-GOMEA performs variations based on linkage models that
indicate which problem variables (i.e., in this case, dwell times at
dwell positions) exhibit some degree of dependency and should
thus be treated together. In the context of black-box optimiza-
tion, linkage models can be learned from the population. Although
even the most comprehensive linkage model employed byMO-RV-
GOMEA, i.e., the linkage tree, can be efficiently learned, perform-
ing linkage learning in every cluster for each generation can incur
some computing time overhead. It could be beneficial and more
efficient if sufficient problem-specific information is available to
construct the linkage models offline. For the BT treatment plan-
ning problem, it can be argued that dwell positions that are close
to each other have stronger interactions than dwell positions that
are far apart. Dwell times at neighboring dwell positions, therefore,
should be treated together when performing variation. e coor-
dinates of all active dwell positions, which are determined from
the CT/MRI scans of the patients, can be used to compute the Eu-
clidean distances between all pairs of dwell positions. Such ge-
ometry information can be directly used as a distance/similarity
metric to construct the linkage tree as in Section 3. is offline-
constructedEuclidean-distance-based linkage tree can be employed
during the optimization process without the need of online linkage
learning in each cluster, potentially improving the effectiveness in
creating promising candidate treatment plans.
4.2 Partial Evaluations
(MO-RV-)GOMEA differs from other evolutionary algorithms in its
genetic-local-search-like variation operator that transforms each
existing (parent) solution into a new (offspring) solution in a step-
wise manner. At each step, a few problem variables’ values (i.e.,
dwell times in this context) are altered, and the changes are only ac-
cepted if they improve the quality of the current solution (i.e., the
candidate treatment plan at hand). Which problem variables are
varied at each step is oen determined by the linkages described
by the employed linkage model such that variables having some
degree of dependency should be jointly treated. In black-box op-
timization, each partially-altered solution needs to be fully evalu-
ated to check for improvements. If the problem is sufficiently un-
derstood, the impact of such local changes can be efficiently com-
puted/approximated using partial evaluations. e evaluation of
a treatment plan involves the computing of the radiation dose re-
ceived at each dose calculation point (see Equation 1) and the com-
puting of DV indices (see Equation 2). e former takes a more
substantial amount of computing time. e matrix-vector multi-
plication in Equation 1, however, does not need to be calculated
completely anew when the vector of dwell times is changed at
only a few elements (i.e., dwell positions). More specifically, the
impact of such changes on the dose distribution can be efficiently
computed by invoking only the columns of the dose-rate matrix R
corresponding with the dwell positions where the dwell times are
altered. Let t be an evaluated treatment plan with the correspond-
ing dose distributiond . Let t ′ be a treatment plan that differs from
t at only a few dwell positions, i.e., t ′ = t + ∆t , in which ∆t has
many zero elements. e dose distribution d ′ associated with t ′
can be computed as:
d
′
= Rt
′
= R(t + ∆t ) = Rt + R∆t = d + R∆t (7)
where the i-th index of R∆t can be computed as:
(R∆t )i =
nT∑
j=1
∆tj,0
Ri j∆tj (8)
which thus only involves the multiplication of the column R∗j of
R with the corresponding non-zero elements ∆tj of ∆t . Note that
in the implementation an entire vector ∆t is not explicitly com-
puted, but rather only the compact vector of non-zero elements in
∆t corresponding to a linkage set in the linkage tree is computed.
1376
GECCO ’17 Companion, July 15-19, 2017, Berlin, Germany Luong et. al.
e step-wise operation of the variation operator of MO-RV-
GOMEA makes it straightforward for partial evaluations to be em-
ployed, if possible. For other existing MOEAs, such as MAMaL-
GaM or NSGA-II, each time a whole offspring solution is created
at once, making partial evaluations impossible.
5 EXPERIMENTS
5.1 Experiment Settings
DICOM files of three anonymized HDR-BT cases for prostate can-
cer from the Academic Medical Center (AMC) were available for
conducting our experiments. DICOM files are loaded into the BT
treatment planning sowareOncentra Brachy, fromwhich the con-
tours of the involved organs (i.e., prostate, seminal vesicles, blad-
der, rectum, and urethra) and the inserted catheter information can
be exported. is extracted information is then used as the input
data for ourmulti-objective optimization algorithm. Similar to clin-
ical practice, we activate all dwell positions inside the two target
volumes: the prostate and seminal vesicles, each with an extended
margin of 5mm while dwell positions within 1mm margin of the
urethra should be kept inactive. In each organ, we uniformly ran-
domly generate 4,000 points, i.e., a total of 20,000 dose calculation
points are employed each time. Such a number of random points is
deemed sufficient for the purpose of performing optimization [9].
We perform experiments with three MO-RV-GOMEA variants
employing three linkage models: the Univariate Factorization (UF)
model where all dwell times are deemed independent from each
other, the Linkage Tree (LT) model which is learned from the pop-
ulation in each generation, and the fixed LT which is constructed
a priori based on the geometry information of active dwell po-
sitions. For each MO-RV-GOMEA we run two seings: 1) full
treatment plan evaluations are always carried out to assess can-
didate treatment plans, and 2) partial evaluations are enabled to
assess partially-altered treatment plans when performing solution
variation. For the purpose of performance comparison between
MO-RV-GOMEA and state-of-the-art MOEAs, we consider NSGA-
II [4] and MAMaLGaM [1]. NSGA-II employs the Simulated Binary
Crossover (SBX [3, 4]) operator to create offspring solutions in real-
valued optimization. MAMaLGaM estimates a Gaussian mixture
distribution over the 35% best solutions in the population and sam-
ples the learned distribution to generate offspring solutions in each
generation. To eliminate the tuning of the population size param-
eter, for all algorithms, we implement the interleaved multistart
scheme as introduced in [2]. For every patient case, we run each al-
gorithm 30 times independently. Each optimization run is allowed
to operate 1 hour to obtain an approximation set of non-dominated
plans.
We use the hypervolume [15] to compare the performance of
MOEAs. e hypervolume can be intuitively defined as the volume
(or area in the case of bi-objective optimization) in the objective
space that is covered by a set of non-dominated solutions and a
reference point, which is a point that can be selected such that it
will be dominated by any possible solutions. Here, since the range
of the two objectives LCI and LSI is [0, 1], we can simply choose
(−0.1,−0.1) as the reference point.
5.2 Results
Figure 1 shows the graphs of hypervolume development along the
running time (in seconds) averaged over 30 runs of each optimiza-
tion algorithm for the three patient cases. To support some of our
observations from the figure, we use the Mann-Whitney-Wilcoxon
statistical hypothesis test for equality of medians with p < 0.05 to
see whether the final result obtained by one algorithm is statisti-
cally different from that of another algorithm. When partial eval-
uations are not enabled, i.e., MO-RV-GOMEA carries out a normal
full evaluation every time a candidate solution needs to be assessed,
all MO-RV-GOMEA variants are outperformed by both NSGA-II
and MAMaLGaM. Using totally full evaluations is inefficient for
MO-RV-GOMEA because treatment plan evaluation is a compu-
tationally expensive operation and the algorithm most oen only
modifies an existing solution in a few variables at each step before
fully constructing a new (offspring) solution, which differs from
otherMOEAs likeNSGA-II andMAMaLGaM that generate awhole
new solution at once. While the slopes of the hypervolume devel-
opment graphs of NSGA-II and MAMaLGaM flaen out at the end
of the optimization runs, suggesting that both algorithms nearly
converge, the ones of MO-RV-GOMEA variants still steepen up,
indicating that they are still in the middle of the search. Note that
using different linkage models that capture only higher-order de-
pendencies of a certain minimum degree could have a substantial
impact here and make the difference much smaller. However, us-
ing partial evaluations, as is possible here, could make such search
for highly suitable linkage structures superfluous.
Indeed, when partial evaluations are enabled, all variants ofMO-
RV-GOMEAare substantially accelerated, outperformingbothMA-
MaLGaM and NSGA-II in the cases of patients 2 and 3. At the
termination time of one hour, in all three cases, MO-RV-GOMEA
with the fixed LT and partial evaluations is the best algorithm, ob-
taining Pareto fronts with the highest hypervolume values, which
are found to be statistically significantly different from the other
MO-RV-GOMEA variants and the other MOEAs. erefore, we
consider the fixed LT with partial evaluations as the most suitable
configuration for MO-RV-GOMEA to tackle the BT treatment plan-
ning problem and we only consider this configuration in the fol-
lowing discussion.
Figure 2 shows the Pareto fronts of non-dominated plans ob-
tained by NSGA-II, MAMaLGaM, and MO-RV-GOMEA for the 3
cases. Each Pareto front is the combination of the 30 approxima-
tion sets obtained at the end of the 30 optimization runs of each
algorithm. Our formulations of the two objectives LCI and LSI
(see Section 2.4) imply that treatment plans satisfying all clinical
requirements (in Table 1) should equal to, or (Pareto-)dominate,
the point (0.95, 0.75). Graphically, clinically-acceptable treatment
plans can be located in the top-right corner of the graphs between
(0.95, 0.75) and (1, 1). Pareto fronts shown in Figure 2 indicate that
treatment plans that satisfy all clinical requirements are achievable
in all three cases. e Pareto fronts obtained by MO-RV-GOMEA
are always beer than the ones obtained by NSGA-II and MAMaL-
GaM. It can be clearly seen that in the clinically-acceptable cor-
ner, the solutions of MO-RV-GOMEA (Pareto-)dominate the solu-
tions of bothNSGA-II andMAMaLGaM, suggesting that exploiting
the information of linkages between problem variables (i.e., dwell
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Figure 1: e average hypervolume values of the Pareto fronts of optimization algorithms over time.
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Figure 2: Pareto fronts combined from 30 optimization runs of each algorithm aer running for 1 hour.
times) benefits the optimization algorithm in reaching treatment
plans of higher quality.
Since the treatment planning process in practice is highly time-
constrained, which should not take more than 1 hour, it is inter-
esting to investigate the results of optimization algorithms with a
shorter time span. Figure 3 shows the Pareto fronts combined from
30 optimization runs of each algorithm aer running for 10 min-
utes. It can be seen that, in all three cases, MO-RV-GOMEA can ob-
tain Pareto fronts of high-quality treatment plans much faster than
NSGA-II and MAMaLGaM. Especially in the clinically-acceptable
corner, the treatment plans found byMO-RV-GOMEA clearly dom-
inate the results of NSGA-II and MAMaLGaM. Comparing Figure
2 and Figure 3, the improvements of the Pareto fronts of MO-RV-
GOMEA are not as substantial as the improvements of the Pareto
fronts of NSGA-II andMAMaLGaMobtained by an extra 50minute
runtime. is suggests that MO-RV-GOMEA can simply be run in
only 10 minutes to achieve the results of the other MOEAs running
for 1 hour. Overall, the results appear very promising. As a first
next step, these sets of treatment plans exhibiting natural trade-
offs in BT treatment planning will be analyzed with clinical ex-
perts and rigorously compared with clinically-approved treatment
plans.
6 CONCLUSION
In this paper, we presented how the BT treament planning problem
can be formulated and tackled by a novel multi-objective optimiza-
tion approach in which only two objectives are considered, rather
than having a single objective for each clinical objective that is typi-
cally found in clinical requirements. In particular, those clinical ob-
jectives that express tomaximize irradiation are grouped in one ob-
jective, as are those that express to minimize irradiation. By care-
fully remapping these clinical objectives and using the worst one
in each group as the value in the bi-objective optimization function,
a risk-averse, guaranteed minimal performance model is obtained
such that the results of which are straightforward to interpret. We
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Figure 3: Pareto fronts combined from 30 optimization runs of each algorithm aer running for 10 minutes.
proposed that the recently-introduced MO-RV-GOMEA, a promis-
ing optimizer that can exploit hierarchical linkages between prob-
lem variables, is an especially promising optimizer to tackle the
problem because MO-RV-GOMEA allows partial evaluations to be
carried out when existing solutions are only locally altered at a
few variables, we suggested that this feature can be exploited us-
ing the dependencies between dwell positions and their geometry
information. Using linkage exploitation and partial evaluations,
MO-RV-GOMEA is capable of outperforming both thewidely-used
MOEA NSGA-II and the state-of-the-art MOEDA MAMaLGaM in
obtaining a set of high-quality treatment plans in a 1/6 fraction of
the planning time budget. is, together with the fact that Pareto
fronts are obtained that insightfully visualize the main trade-off in
BT treatment planning, leads us to conclude that MO-RV-GOMEA
is a very promising algorithm to develop and use further for the
automated design of BT treatment plans.
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